Heron Therapeutics (HRTX) Competitors $2.16 +0.02 (+0.70%) Closing price 07/3/2025 03:53 PM EasternExtended Trading$2.16 0.00 (0.00%) As of 07/3/2025 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HRTX vs. CVAC, CALT, GPCR, AUPH, NAGE, AMPH, DYN, PAHC, BGM, and ABCLShould you be buying Heron Therapeutics stock or one of its competitors? The main competitors of Heron Therapeutics include CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Structure Therapeutics (GPCR), Aurinia Pharmaceuticals (AUPH), Niagen Bioscience (NAGE), Amphastar Pharmaceuticals (AMPH), Dyne Therapeutics (DYN), Phibro Animal Health (PAHC), BGM Group (BGM), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry. Heron Therapeutics vs. Its Competitors CureVac Calliditas Therapeutics AB (publ) Structure Therapeutics Aurinia Pharmaceuticals Niagen Bioscience Amphastar Pharmaceuticals Dyne Therapeutics Phibro Animal Health BGM Group AbCellera Biologics Heron Therapeutics (NASDAQ:HRTX) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment. Is HRTX or CVAC more profitable? CureVac has a net margin of 35.44% compared to Heron Therapeutics' net margin of -5.24%. CureVac's return on equity of 30.89% beat Heron Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Heron Therapeutics-5.24% N/A -3.43% CureVac 35.44%30.89%25.54% Which has more risk and volatility, HRTX or CVAC? Heron Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, CureVac has a beta of 2.53, meaning that its stock price is 153% more volatile than the S&P 500. Does the media refer more to HRTX or CVAC? In the previous week, Heron Therapeutics had 2 more articles in the media than CureVac. MarketBeat recorded 3 mentions for Heron Therapeutics and 1 mentions for CureVac. Heron Therapeutics' average media sentiment score of 0.97 beat CureVac's score of -0.17 indicating that Heron Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heron Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CureVac 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in HRTX or CVAC? 80.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 5.9% of Heron Therapeutics shares are held by insiders. Comparatively, 2.2% of CureVac shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has higher valuation & earnings, HRTX or CVAC? CureVac has higher revenue and earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHeron Therapeutics$144.29M2.29-$13.58M-$0.06-36.08CureVac$579.18M2.09$175.50M$0.925.86 Do analysts rate HRTX or CVAC? Heron Therapeutics currently has a consensus target price of $5.00, indicating a potential upside of 130.95%. CureVac has a consensus target price of $6.83, indicating a potential upside of 26.66%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Heron Therapeutics is more favorable than CureVac.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heron Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00CureVac 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 SummaryHeron Therapeutics and CureVac tied by winning 8 of the 16 factors compared between the two stocks. Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HRTX vs. The Competition Export to ExcelMetricHeron TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$335.64M$2.43B$5.54B$9.05BDividend YieldN/A1.78%5.24%4.02%P/E Ratio-36.088.9827.4320.23Price / Sales2.29682.84422.11118.64Price / CashN/A158.5936.8958.07Price / Book-9.844.588.045.67Net Income-$13.58M$31.34M$3.18B$249.13M7 Day Performance1.17%3.25%2.89%3.28%1 Month Performance8.25%7.08%3.70%5.56%1 Year Performance-24.56%0.17%36.15%21.12% Heron Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HRTXHeron Therapeutics4.0557 of 5 stars$2.17+0.7%$5.00+130.9%-21.8%$335.64M$144.29M-36.08300News CoverageCVACCureVac4.6434 of 5 stars$5.43+0.9%$6.83+25.8%+72.9%$1.22B$579.18M5.90880CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180GPCRStructure Therapeutics2.9315 of 5 stars$20.74-1.6%$76.17+267.2%-44.9%$1.19BN/A-23.84136Positive NewsAUPHAurinia Pharmaceuticals3.117 of 5 stars$8.47-2.0%$11.50+35.8%+38.3%$1.14B$235.13M30.25300NAGENiagen Bioscience1.3651 of 5 stars$14.41+1.3%$19.50+35.3%N/A$1.14B$107.93M84.76120AMPHAmphastar Pharmaceuticals4.3747 of 5 stars$22.96-0.5%$32.33+40.8%-39.9%$1.08B$730.66M8.322,028News CoverageDYNDyne Therapeutics3.5129 of 5 stars$9.52-0.5%$41.13+332.0%-73.5%$1.08BN/A-2.65100PAHCPhibro Animal Health3.6455 of 5 stars$25.54-0.5%$21.80-14.6%+63.3%$1.04B$1.02B32.741,940BGMBGM GroupN/A$10.59-11.5%N/AN/A$1.03B$25.10M0.00298ABCLAbCellera Biologics2.4878 of 5 stars$3.43-5.0%$8.33+143.0%+40.4%$1.02B$28.83M-6.12500High Trading Volume Related Companies and Tools Related Companies CureVac Competitors Calliditas Therapeutics AB (publ) Competitors Structure Therapeutics Competitors Aurinia Pharmaceuticals Competitors Niagen Bioscience Competitors Amphastar Pharmaceuticals Competitors Dyne Therapeutics Competitors Phibro Animal Health Competitors BGM Group Competitors AbCellera Biologics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HRTX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
